PGS Publication: PGP000042

Publication Information (EuropePMC)
Title Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting.
PubMed ID 28223407(Europe PMC)
doi 10.1161/CIRCULATIONAHA.116.024436
Publication Date Feb. 21, 2017
Journal Circulation
Author(s) Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, Sartori S, Fuster V, Reilly DF, Butterworth A, Rader DJ, Ford I, Sattar N, Kathiresan S.
Released in PGS Catalog: Dec. 18, 2019

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported

PGS Developed By This Publication

Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution
GWAS
Dev
Eval
Scoring File (FTP Link)
PGS000057
(CHD57)
PGP000042 |
Natarajan P et al. Circulation (2017)
Coronary heart disease coronary artery disease 57
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000057/ScoringFiles/PGS000057.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM000144 PGS000057
(CHD57)
PSS000091|
Ancestry Not Reported|
2,440 individuals
PGP000042 |
Natarajan P et al. Circulation (2017)
Reported Trait: Coronary heart disease (incident) HR (highest vs. lowest quintile of PGS): 1.66 [1.21, 2.29] age, sex, diabetes meliitus status, smoking status, LDL cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive medication status, family history of CHD
PPM000145 PGS000057
(CHD57)
PSS000090|
Ancestry Not Reported|
1,154 individuals
PGP000042 |
Natarajan P et al. Circulation (2017)
Reported Trait: Coronary artery calcification OR: 1.32 [1.04, 1.68] OR (highest vs. lowest quintile of PGS): 2.51 [1.08, 5.85] age, sex, diabetes meliitus status, smoking status, LDL cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive medication status, family history of CHD
PPM000146 PGS000057
(CHD57)
PSS000089|
Ancestry Not Reported|
4,392 individuals
PGP000042 |
Natarajan P et al. Circulation (2017)
Reported Trait: Carotid artery plaque burden β: 1.097 [1.022, 1.178] age, sex, diabetes meliitus status, smoking status, LDL cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive medication status, family history of CHD

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000089 Total carotid plaque burden (mm2) 4,392 individuals Range = [55.0, 80.0] years NR BioImage
PSS000090 Total coronary arterial clacification (CAC) was coded as a a dichotomous outcome variable (CAC>0 versus CAC=0), and quantified by the Agatston method Mean = 15.0 years 1,154 individuals Range = [32.0, 47.0] years NR CARDIA
PSS000091 Nonfatal myocardial infarction or death from CHD Mean = 13.5 years
Sd = 2.8 years
2,440 individuals,
100.0 % Male samples
Mean = 55.1 years
Sd = 5.5 years
NR NR Participants were all men hypercholesterolemia but without a history of myocardial infarction, allocated to the placebo group